Innovations on cancer diagnostics are what AviaraDx, Inc. brought to the market.


© meneldur



Two new oncology tests have been launched for the classification of metastatic cancer and identification of patients with estrogen receptor positive (ER+) breast cancer who are at high risk of recurrence and also those unlikely to respond favorably to standard adjuvant endocrine therapy.

The said tests are the following:

CancerTYPE ID™

Assists physicians in diagnosing metastatic cancer types based on a 92-gene expression assay that is capable of classifying 39 tumor types as well as 64 cancer subtypes. The results help clinicians quickly identify the primary tumor site and avoid unnecessary repetitive imaging and immunohistological procedures in attempting to establish the cancer origin. Successful cancer classification is critical for physicians to select the appropriate treatment regimen.

H/I™ (HOXB13/IL17BR)

Assists physicians in determining the optimal treatment for patients with ER positive, node-negative breast cancer by using two newly developed gene-based biomarkers to evaluate the risk of recurrence and probable response to endocrine therapy. The test is the first tool designed to identify the 10 to 20% of ER positive breast cancers that will relapse within five to 10 years when treated with standard endocrine therapy, enabling oncologists to recommend more aggressive regimens to help improve clinical outcomes.

Here's the good news though: The tests (based on proprietary AviaraDx molecular technologies) are New York state-approved and available through the company's CAP-certified CLIA laboratory. [Both can utilize small formalin-fixed and Paraffin-embedded (FFPE) tissue samples easily available from imaging-guided needle biopsies.]

There you go. Read more.

[Thanks to Laura Baumgartner for the hat tip!]